For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
search
Quick Order bolt
Request Quote sms
Documents
Peptide Purification Method Development: Application for the Purification of Bivalirudin (TN-1129)
We present the purification method development and scale up experiments performed on a crude sample of Bivalirudin prepared by solid phase synthesis.

Peptide Purification Method Development: Application for the Purification of Bivalirudin (TN-1129)

We present the purification method development and scale up experiments performed on a crude sample of Bivalirudin prepared by solid phase synthesis.
Document Type:
Technical Notes
Target Industries:
Biopharmaceutical Analysis, Pharmaceutical
Techniques:
HPLC, HPLC Reversed Phase, Preparative LC
Brands:
Axia, Gemini, Luna HPLC Columns, Synergi
Separation Modes:
Reversed Phase
Phases:
Gemini C18, Luna C18(2), Luna C8(2), Luna Phenyl-Hexyl, Synergi Polar-RP
save_alt Download
favorite_border
Phenomenex
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide
Danaher
Connect With Us
Phenomenex
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide

Products and Services

Products

Techniques

Industries

Quick Order

Support

Product Method Support

Product Troubleshooting

Contact Us

CQA CofA

Our company

About Phenomenex

Blog

News

Danaher Life Sciences

Terms and Conditions Privacy Statement Quality Policy Terms of Use Trademarks CA Supply Chains Act CA Consumer Privacy Act Cookie Policy Impressum
© 2024  Phenomenex Inc. All rights reserved.